Viveve Medical (VIVE) 10-K 16 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 08, 2018	Jun. 30, 2017
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		31,233,972
Entity Public Float			$ 93,750,710
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 20,730	$ 8,086
Accounts receivable, net of allowance for doubtful accounts of $221 and $0 as of December 31, 2017 and 2016, respectively	6,213	2,091
Inventory	2,390	2,687
Prepaid expenses and other current assets	2,741	1,066
Total current assets	32,074	13,930
Property and equipment, net	1,303	483
Investment in limited liability company	2,500
Other assets	202	136
Total assets	36,079	14,549
Current liabilities:
Accounts payable	4,799	3,086
Accrued liabilities	4,605	2,186
Note payable, current portion		1,867
Total current liabilities	9,404	7,139
Note payable, noncurrent portion	28,948	7,762
Other noncurrent liabilities	327	53
Total liabilities	38,679	14,954
Commitments and contingences (Note 8)
Stockholders’ deficit:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2017 and 2016; no shares issued
Common stock, $0.0001 par value; 75,000,000 shares authorized as of December 31, 2017 and 2016; 19,503,558 and 10,661,201 shares issued and outstanding as of December 31, 2017 and 2016, respectively	2	1
Additional paid-in capital	102,979	68,216
Accumulated deficit	(105,581)	(68,622)
Total stockholders’ deficit	(2,600)	(405)
Total liabilities and stockholders’ deficit	$ 36,079	$ 14,549

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts receivable, allowance for doubtful accounts	$ 221	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	19,503,558	10,661,201
Common stock, shares outstanding (in shares)	19,503,558	10,661,201

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 15,288	$ 7,141
Cost of revenue	7,844	4,612
Gross profit	7,444	2,529
Operating expenses:
Research and development	12,343	8,365
Selling, general and administrative	28,831	12,868
Total operating expenses	41,174	21,233
Loss from operations	(33,730)	(18,704)
Interest expense, net	(3,169)	(1,370)
Other expense, net	(60)	(37)
Comprehensive and net loss	$ (36,959)	$ (20,111)
Net loss per share:
Basic and diluted (in dollars per share)	$ (2.11)	$ (2.18)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	17,496,942	9,222,348

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	June 2016 Offering [Member]Common Stock [Member]	June 2016 Offering [Member]Additional Paid-in Capital [Member]	June 2016 Offering [Member]Common Stock Including Additional Paid in Capital [Member]	June 2016 Offering [Member]	March 2017 Offering [Member]Common Stock [Member]	March 2017 Offering [Member]Additional Paid-in Capital [Member]	March 2017 Offering [Member]Common Stock Including Additional Paid in Capital [Member]	March 2017 Offering [Member]	November 2017 ATM Facility [Member]Common Stock [Member]	November 2017 ATM Facility [Member]Additional Paid-in Capital [Member]	November 2017 ATM Facility [Member]Common Stock Including Additional Paid in Capital [Member]	November 2017 ATM Facility [Member]Retained Earnings, Appropriated [Member]	November 2017 ATM Facility [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Including Additional Paid in Capital [Member]	Retained Earnings, Appropriated [Member]	Total
Balances as of January 1, 2016 (in shares) at Dec. 31, 2015																7,490,288
Balances as of January 1, 2016 at Dec. 31, 2015																$ 52,447	$ (48,511)	$ 3,936
Reverse stock split - rounding adjustment (in shares)																2,361
Stock-based compensation expense															$ 707	$ 188		895
Issuance of restricted stock awards to employees for performance bonuses																246		246
Issuance of restricted stock awards to directors and consultants (in shares)														18,792
Issuance of restricted stock awards to directors and consultants															125			125
Issuance of warrants															20	$ 142		162
Exercise of warrants (in shares)														35,490		6,250
Exercise of warrants															65	$ 27		$ 92
Exercise of stock options (in shares)																3,020		3,020
Exercise of stock options																$ 14		$ 14
Reclassification upon change in corporate domicile (in shares)														7,501,919		(7,501,919)
Reclassification upon change in corporate domicile														$ 1	53,063	$ (53,064)
Private placement offering, net of issuance costs (in shares)	3,105,000
Private placement offering, net of issuance costs		$ 13,886		$ 13,886
Issuance of warrant in connection with note payable															350			350
Net loss																	(20,111)	(20,111)
Balances (in shares) at Dec. 31, 2016														10,661,201
Balances at Dec. 31, 2016														$ 1	68,216		(68,622)	(405)
Stock-based compensation expense															1,646			1,646
Issuance of restricted stock awards to employees for performance bonuses
Issuance of restricted stock awards to directors and consultants (in shares)														77,783
Issuance of restricted stock awards to directors and consultants															226			226
Exercise of warrants (in shares)														4,701
Exercise of warrants															20			$ 20
Exercise of stock options (in shares)														7,730				7,730
Exercise of stock options															31			$ 31
Private placement offering, net of issuance costs (in shares)					8,625,000				59,249
Private placement offering, net of issuance costs					$ 1	$ 31,439		$ 31,440		$ 125			$ 125
Issuance of warrant in connection with note payable															940			940
Net loss																	(36,959)	(36,959)
Issuance of restricted common shares (in shares)														35,000
Issuance of restricted common shares															260			260
Issuance of common shares from employee stock purchase plan (in shares)														17,894
Issuance of common shares from employee stock purchase plan															76			76
Cashless exercise of warrant (in shares)														15,000
Balances (in shares) at Dec. 31, 2017														19,503,558		0
Balances at Dec. 31, 2017														$ 2	$ 102,979		$ (105,581)	$ (2,600)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (36,959)	$ (20,111)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	(221)
Depreciation and amortization	449	111
Stock-based compensation	1,872	1,020
Fair value of restricted common shares issued in lieu of cash	260
Fair value of warrants issued		162
Non-cash interest expense	1,049	456
Changes in assets and liabilities:
Accounts receivable	(3,901)	(1,498)
Inventory	(67)	(1,237)
Prepaid expenses and other current assets	(1,675)	162
Other noncurrent assets	(66)	2
Accounts payable	1,713	1,654
Accrued and other liabilities	2,419	1,192
Other noncurrent liabilities	274
Net cash used in operating activities	(34,853)	(18,087)
Cash flows from investing activities:
Investment in limited liability company	(2,500)
Purchase of property and equipment	(905)	(256)
Net cash used in investing activities	(3,405)	(256)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	31,565	13,886
Proceeds from note payable	29,210	9,910
Repayments of note payable	(10,000)	(4,833)
Proceeds from issuance of common shares from employee stock purchase plan	76
Proceeds from exercise of stock options	31	14
Proceeds from exercise of warrant	20	92
Net cash provided by financing activities	50,902	19,069
Net increase in cash and cash equivalents	12,644	726
Cash and cash equivalents - beginning of period	8,086	7,360
Cash and cash equivalents - end of period	20,730	8,086
Supplemental disclosure:
Cash paid for interest	2,066	803
Cash paid for income taxes		1
Supplemental disclosure of cash flow information as of end of period:
Issuance of warrant in connection with note payable	940	350
Issuance of note payable in settlement of accrued interest	495
Net transfer of equipment between inventory and property and equipment	364	99
Restricted stock awards granted to employees for 2015 accrued bonuses		$ 246

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s health industry in some countries by marketing Geneveve™ as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity. Public Offering The Company established an “ at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, November 8, 2017, may $25,000,000 “November 2017 December 31, 2017, 59,249 November 2017 $125,000. On March 22, 2017, March 2017 8,625,000 $4.00 $34,500,000. $31,440,000 . On June 17, 2016, June 2016 3,105,000 $5.00 $15,525,000. $13,886,000. Change of Corporate Domicile On May 9, 2016, May 10, 2016, $0.0001

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U .S . GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three ’s cash and cash equivalents are deposited in demand accounts primarily at one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no eristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company ’s products likely require clearance or approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity for improved sexual function, and for vaginal rejuvenation depending on the relevant country-specific clearance or approval that it refers to as the Viveve System . The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2017 , two 35% December 31, 2016, three 78% There are no 10% ’s revenue during the years ended December 31, 2017 2016 . As of December 31, 2017, two 57 December 31, 2016, three 81% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not Occasionally, payment terms of up to six may six not $221,000 zero December 31, 2017 2016, Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2017 $1,990,000 $400,000 December 31, 2016 $2,506,000 $181,000 first first not As part of the Company ’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2017 2016. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight -line method over their estimated useful lives of three seven Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not Revenue Recognition The Company recognizes revenue net of sales taxes from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company also sells a small number of extended service agreements on certain products for the period subsequent to the normal one December 31, 2017 2016. When a sales agreement involves multiple deliverables, such as extended warranties, the multiple deliverables are evaluated to determi ne the units of accounting. Judgment is required to properly identify the accounting units of multiple element transactions and the manner in which revenue is allocated among the accounting units. Judgments made, or changes to judgments made, may Revenue related to the multiple deliverables is allocated to each unit of accounting using the selling price hierarchy. Consistent with accounting guidance, the selling price is based upon vendor specific objective evidence (“VSOE”). If VSOE is not third December 31, 2017 2016, no The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products . Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not lly to recognize ( 1 2 3 We utilize a three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2017, no Product Warranty The Company ’s products are generally subject to a one not Shipping and Handling Costs The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue. Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2017 2016. Research and Development Research and development costs are charged to operations a s incurred. Research and development costs include, but are not Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company ’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2017 2016. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not cal merits of the position. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not 12 Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subje ct to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2017 2016, Net Loss per Share The Company ’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2017 2016 Stock options to purchase common stock 2,694,224 1,909,764 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards 10,000 58,155 Recently Issued and Adopted Accounting Standards In May 2014, IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014 09, 606 606 606” five not December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 ( 2015 14 2016 08 2016 10 2016 10 May 2016, 2016 12, 606 not May 2014. The Company did not this guidance, and accordingly, will adopt this new standard effective January 1, 2018. 606 605 January 1, 2018, January 1, 2018. As part of its preliminary evaluation, the Company has also considered the impact of the guidance in ASC 340 40, “Other Assets and Deferred Costs; Contracts with Customers”, with respect to capitalization and amortization of incremental costs of obtaining a contract. This guidance, requires the capitalization of all incremental costs that the Company incurs to obtain a contract with a customer that it would not not not not The Company has set up a team for the implementation of the new revenue recognition accou nting standard. Based on preliminary analysis, the Company expects that the new standard will not 606. In July 2015, 2015 11, Simplifying the Measurement of Inventory” (“ASU 2015 11” 2015 11 not first 2015 11 January 1, 2017. not In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, In March 2016, 2016 09, Compensation – Stock Compensation (Topic 718 January 1, 2017 not In August 2016, No. 2016 15, Statement of Cash Flows, Classification of Certain Cash Receipts and Cash Payments (Topic 230 zero December 15, 2017, January 1, 2018 not In August 2016, No. 2016 18, “Statement of Cash Flows, Restricted Cash (Topic 230 December 15, 2017, January 1, 2018 not In May 2017, No. 2017 09, Compensation - Stock Compensation (Topic 718 may 718. December 15, 2017, January 1, 2018 not We have reviewed other recent accounting pronouncements and concluded they are either not no ents as a result of future adoption.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active mark ets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fai r value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no December 31, 201 7 2016 . The carrying amounts of the Company ’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2017 2016 There were no

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, Net Property and equipment, net, consisted of the following as of December 31, 201 7 2016 Life December 31, (in years) 2017 2016 Medical equipment 5 $ 1,299 $ 657 Computer equipment 3 193 83 Leasehold Improvements 3 200 - Furniture and fixtures 7 340 57 2,032 797 Less: Accumulated depreciation and amortization (729 ) (314 ) Property and equipment, net $ 1,303 $ 483 Depreciation and amortization expense for the years ended December 31, 2017 2016 $449,000 $111,000,

Note 5 - Investment in Limited

Note 5 - Investment in Limited Liability Company	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	5. Investment in Limited Liability Company On August 8, 2017, Distributorship Agreement”) with InControl Medical, LLC (“ICM”), a Wisconsin limited liability company focused on women's health, pursuant to which the Company will directly market, promote, distribute and sell ICM’s products to licensed medical professional offices and hospitals. Under the terms of the Distributorship Agreement, ICM agreed to not third romote, distribute or sell any of the licensed products to any licensed medical professional offices and hospitals in the United States. In exchange, the Company agreed to not December 31, 2017, 1,200 $94,000 December 31, 2017. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limite d liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not December 31, 2017, 11% three December 31, 2017,

Note 6 - Accrued Liabilities

Note 6 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6 . Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 201 7 2016 December 31, December 31, 2017 2016 Accrued bonuses $ 1,597 $ 1,102 Accrued sales commission 1,067 115 Accrued payroll and other related expenses 488 249 Accrued professional fees 562 483 Accrued interest 447 65 Accrued sales & use tax 149 39 Other accruals 295 133 Total accrued liabilities $ 4,605 $ 2,186

Note 7 - Note Payable

Note 7 - Note Payable	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	7 . Note Payable On June 20, 2016, January 13, 2017 ( 2016 $10,000,000 two $7,500,000 $2,500,000. $10,000,000 June 20, 2016. 2016 4.00% 2016 May 2017 ( In connection with the 2016 the Company issued a 10 100,402 $4.98 9 On May 22, 2017, 2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 eeds (after deducting loan origination costs and other fees and expenses incurred in connection with the 2017 may The 2017 six four 2017 fixed rate of 12.50%, 4.0% may, December 31, 2017, $495,000 December 31, 2017. 5% December 31, 2017, $132,000 The Company may erest under the 2017 first five no As security for its obligations under the 2017 reement, the Company entered into security agreements with CRG whereby the Company granted CRG a lien on substantially all of the Company’s assets, including intellectual property. The terms of the 2017 ain financial and other covenants. These covenants require the Company to maintain cash and cash equivalents of $2.0 2022, not 2.0 2017 December 31 , 2017, In connection with the 2017 o 10 222,049 $9.50 9 As of December 31, 2017, Year Ending December 31, 2018 $ 2,668 2019 2,778 2020 2,901 2021 16,672 2022 19,306 Thereafter 6,221 Total payments 50,546 Less: Amount representing interest (20,051 ) Present value of obligations 30,495 Less: Unamortized debt discount (1,547 ) Note payable, noncurrent portion $ 28,948

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8 . Commitments and Contingencies Operating Lease In January 2012, in Sunnyvale, California. The lease agreement, as amended in September 2016, March 2012 March 2018. On February 1, 2017, Sublease”) for approximately 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 per rentable square foot during the second third $22,000. $88,000 Rent expense for the years ended December 31, 2017 2016 $442,000 $236,000, As of December 31, 2017, Year Ending December 31, 2018 $ 338 2019 264 2020 112 Total minimum lease payments $ 714 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifi es, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not Legal Proceedings On March 11, 2016, former employee's negligent performance of certain work duties. The demand seeks damages for lost profits, along with attorney's fees, interest, and costs. The former employee filed a counterclaim in the proceeding, alleging discrimination, retaliation, wrongful termination, and various claims for alleged wage and hour violations under the California Labor Code, stemming from the cessation of her employment with the Company. The former employee seeks damages for lost wages, punitive damages, statutory lties, injunctive relief, and attorney’s fees, interest and costs. On October 21, 2016, ’s U.S. Patent Number 8,961,511 “‘511

Note 9 - Common Stock

Note 9 - Common Stock	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9 . Common Stock The Company established , through the filing of a prospectus supplement to its shelf registration statement on Form S- 3 November 8, 2017), may $25,000,000 “November 2017 December 31, 2017, 59,249 November 2017 $125,000. On May 19, 2017, 35,000 $7.42 $260,000. On March 22, 2017, March 2017 sued an aggregate of 8,625,000 $4.00 $34,500,000. $31,440,000 . On June 17, 2016, June 2016 3,105,000 ding the exercise of the underwriters’ overallotment option, at a public offering price of $5.00 $15,525,000. $13,886,000. Warrants for Common Stock As of December 31, 201 7, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622 I n connection with the Loan and Security Agreement entered into on September 30, 2014, February 19, 2015, May 14, 2015, November 30, 2015 March 18, 2016 ( “2014 1 58,962 $4.24 June 2016 2016 June 30, 2016. December 31, 2016, $387,000, August 2016 17,295 In conjunction with the second 2014 May 2015, a total of 3,125 $2.96 September 30, 2015. July 2016 885 In connection with the 2016 100,402 $4.98 issuance to be $350,000. $90,000, May 2017 2017 June 30, 2017. December 31, 2017 2016, $371,000 $69,000, . In connection with the 2017 Loan Agreement, the Company issued warrants to purchase a total of 222,049, $9.50 ten $940,000 0%, 55.1%, 2.25% ten $790,000, December 31, 2017, $183,000 December 31, 2017, $1,547 ,000. A total of 4,701 25,268 September 30, 2014, during the years ended December 31, 2017 2016, No year ended December 31, 2017. 1,094 two October 2014 December 31, 2016 not The total stock-based compensation expense related to warrants issued was zero $162,000 December 31, 2017 2016,

Note 10 - Summary of Stock Opti

Note 10 - Summary of Stock Options	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10 . Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards from three ’s 2005 “2005 2006 “2006 2013 “2013 There are currently no 2005 no are available for future awards. The 2006 and was terminated in conjunction with the merger that took place on September 23, 2014 2006 2006 2006 38,378 no $10.49 4.88 The 2013 the Company’s board of directors and approved by its stockholders. The 2013 2013 may may -based awards or dividend equivalent rights. Awards may 2013 may not 10 may four may 424 10% no 110% not five On August 22, 2016, ’s stockholders approved an amendment to the 2013 first January, 2013 4% December 23, 2016, 2017 2013 523,209 2,000,000 2,523,209 January 1, 2017. August 15, 2017, 2013 2013 2,523,209 4,000,000 December 6, 2017, 2018 2013 780,143 4,000,000 4,780,143 January 1, 2018 . As of December 31, 201 7, 2013 2,655,846 1,186,527 $5.73 8.64 Activity under the 2005 the 2006 2013 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, December 31, 2015 1,022,195 $ 6.47 9.37 $ 1,194,180 Options granted 978,966 $ 6.00 Options exercised (3,020 ) $ 4.80 Options cancelled (88,377 ) $ 7.41 Options outstanding, December 31, 2016 1,909,764 $ 6.19 9.12 $ 211,396 Options granted 1,000,985 $ 5.68 Options exercised (7,730 ) $ 4.02 Options cancelled (208,795 ) $ 8.88 Options outstanding, December 31, 2017 2,694,224 $ 5.80 8.58 $ 249,154 Vested and exercisable and expected to vest, end of period 2,539,133 $ 5.80 8.55 $ 239,624 Vested and exercisable, end of period 843,008 $ 5.86 7.65 $ 116,261 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company ’s closing share price as of December 31, 2017 . The options outstanding and exercisable as of December 31, 2017 Options Outstanding Options Exercisabl e Weighte d Numbe r Weighte d Averag e Numbe r Weighte d Outstanding Averag e Remainin g Exercisabl e Averag e Range o f as o f Exercis e Contractua l as o f Exercis e Exercise Price s December 31, 201 7 Pric e Term (Years ) December 31, 201 7 Pric e $2.64 12,500 $ 2.64 7.37 8,334 $ 2.64 $3.68 - $3.76 66,876 $ 3.76 7.10 47,371 $ 3.76 $4.46 - $5.01 542,829 $ 4.72 8.51 183,555 $ 4.75 $5.22 557,358 $ 5.22 8.94 146,696 $ 5.22 $5.46 - $5.67 365,000 $ 5.58 9.72 - $ - $6.00 557,753 $ 6.00 7.96 278,880 $ 6.00 $6.24 - $6.61 122,038 $ 6.44 8.18 36,766 $ 6.32 $7.00 - $7.92 431,492 $ 7.65 8.75 103,028 $ 7.72 $9.92 38,135 $ 9.92 4.89 38,135 $ 9.92 $56.00 - $296.00 243 $ 100.46 2.96 243 $ 100.46 2,694,224 $ 5.80 8.58 843,008 $ 5.86 Restricted Stock Awards In January 2016, RSAs”) for 39,494 2013 2015 $6.24 89 September 2016. one January 2017 39,405 In August 2016, 5,998 2013 $7.89 ’s common stock on the award date. The RSAs were fully vested on the date of grant and 5,998 . In September 2016, 25,000 $7.58 d on the market price of the Company’s common stock on the award date. The RSA vests over one 1/4th December 31, 2017, 25,000 In November 2016, y granted RSAs for 6,544 2013 $5.91 6,544 . In May 2017, 4,797 2013 e fair value of $7.07 4,797 In September 2017, 6,9 47 2013 $5.58 6,947 In October 2017, 7,884 2013 5.55 7,884 In December 2017, 10,000 $4.94 four 1/4 th first December 31, 2017, zero There were 10,000 December 31, 2017 . 2017 In August 2017, ’s 2017 “2017 400,000 2017 may 2,000 2017 85% first three first 2017 October 1, 2017 December 31, 2017, 17,894 December 29, 2017 $4.2245 . As of December 31, 2017, 2017 382,106 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right under the ESPP was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Year Ended December 31, 2017 Expected term (in years) 0.25 Average volatility 61 % Risk-free interest rate 1.06 % Dividend yield 0 % The weighted average grant date fair value of the purchase rights issued under the 2017 December 31, 2017 $1.51 . Stock-Based Compensation During the years ended December 31, 2017 2016, 981,110 919,841 $2.88 $2.63 December 31, 2017 2016 $31,000 $5,000. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over t he requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2017 2016 Expected term (in years) 5 5 Average volatility 59% 49% Risk-free interest rate 1.89% 1.78% Dividend yield 0% 0% During the year ended December 31, 2017 2016, 19,875 59,125 $4.09 $4.60 no December 31, 2017 2016. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2017 2016 Expected term (in years) 10 10 Average volatility 72% 51% Risk-free interest rate 2.38% 2.43% Dividend yield 0% 0% Option-pricing models require the input of various subjective assumptions, including the option ’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the consolidated statements of operations for the years ended December 31, 201 7 2016 Year Ended December 31, 2017 2016 Cost of revenue $ 19 $ - Research and development 252 114 Selling, general and administrative 1,601 906 Total $ 1,872 $ 1,020 As of De cember 31, 2017, $4,547,000. 2.8

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 1 . Income Taxes No come taxes has been recorded due to the net operating losses incurred from inception to date, for which no A reconciliation of the U.S. statutory income tax rate to the Company ’s effective tax rate is as follows: Year Ended December 31, 2017 2016 Income tax provision (benefit) at statutory rate (34 )% (34 )% State income taxes, net of federal benefit (4 )% (2 )% Change in valuation allowance 4 % 33 % Effect of tax legislation 33 % 0 % Other 1 % 3 % Effective tax rate 0 % 0 % The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands): December 31, 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 19,699 $ 16,888 Capitalized start up costs 3,963 5,944 Research and development credits 835 518 Accruals and reserves 1,403 1,095 Fixed assets and depreciation 39 - Total deferred tax assets 25,939 24,445 Deferred tax liabilities: Fixed assets and depreciation - (7 ) Valuation allowance (25,939 ) (24,438 ) Net deferred tax assets $ - $ - The Company has recorded a full valuation allowance for its deferred tax assets based on it past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance increased by approximately $1,501,000 $5,750,000 December 31, 2017 2016, As of December 31, 201 7, $78,858,000 $50,517,000, 2026 . The Company also has federal and California research and development tax credits of approximately $701,000 $623,000, 2026 no Utilization of the NOL and research and development credit carryforwards may ubstantial annual limitation due to ownership changes that have occurred previously or that could occur in the future, as provided by Section 382 1986, may 382, 50 three 382. may 382 no no As of December 31, 20 17, not A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2017 2016 Balance at the beginning of the year $ 268 $ 128 Additions based upon tax positions related to the current year 129 140 Balance at the end of the year $ 397 $ 268 If the ending balance of $397,000 December 31, 2017 none not twelve may The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examinati on due to the carryover of unused net operating losses and tax credits. On December 22, 2017, TCJA”) which makes widespread changes to the Internal Revenue Code, including a reduction in the federal corporate tax rate to 21%, and repatriation of accumulated foreign accumulated earnings and profits , effective January 1, 2018. The Company is required to recognize the effect on deferred tax assets and liabilities of a change in tax rates be recognized in the period the tax rate change was enacted. The carrying value of our U.S. deferred taxes is determined by the enacted U.S. corporate income tax rate. Consequently, the reduction in the U.S. corporate income tax rate impacts the carrying value of our deferred tax assets. Under the new corporate income tax rate of 21%, . The Company has also considered the impact of the transition tax for which it has estimated it does not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	1 2 . Related Party Transactions In June 2006, October 4, 2007. 300 December 31, 2017, 543 37,500 $7,912,000 $6,485,000 December 31, 2017 2016,

Note 13 - Segments and Geograph

Note 13 - Segments and Geographic Information	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 3 . Segments and Geographic Information The Company has determined that it operates as a single operating and reportable segment. Revenue from unaffiliated customers by geographic area was as follows (in thousands): Year Ended December 31, 2017 2016 United States $ 11,004 315 Asia Pacific 3,178 4,946 Europe and Middle East 667 1,489 Latin America 360 382 Canada 79 9 Total $ 15,288 $ 7,141 The Company determines geographic location of its revenue based upon the destination of shipments of its products. The Company ’s long-lived assets by geographic area were as follows (in thousands): Year Ended December 31, 2017 2016 United States $ 1,192 $ 370 Asia Pacific 52 39 Canada 46 2 Latin America 12 - Europe 1 72 Total $ 1,303 $ 483 Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at ea ch balance sheet date.

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	1 4 . Subsequent Events On February 12, 2018, February 2018 11,500,000 $3.00 $34,500,000. $32,380,000, . In January 2018 , the Company sold 208,277 $1,025,000 November 2017 no November 2017

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U .S . GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three ’s cash and cash equivalents are deposited in demand accounts primarily at one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no eristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company ’s products likely require clearance or approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity for improved sexual function, and for vaginal rejuvenation depending on the relevant country-specific clearance or approval that it refers to as the Viveve System . The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2017 , two 35% December 31, 2016, three 78% There are no 10% ’s revenue during the years ended December 31, 2017 2016 . As of December 31, 2017, two 57 December 31, 2016, three 81%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not Occasionally, payment terms of up to six may six not $221,000 zero December 31, 2017 2016,
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2017 $1,990,000 $400,000 December 31, 2016 $2,506,000 $181,000 first first not As part of the Company ’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2017 2016.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight -line method over their estimated useful lives of three seven
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue net of sales taxes from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company also sells a small number of extended service agreements on certain products for the period subsequent to the normal one December 31, 2017 2016. When a sales agreement involves multiple deliverables, such as extended warranties, the multiple deliverables are evaluated to determi ne the units of accounting. Judgment is required to properly identify the accounting units of multiple element transactions and the manner in which revenue is allocated among the accounting units. Judgments made, or changes to judgments made, may Revenue related to the multiple deliverables is allocated to each unit of accounting using the selling price hierarchy. Consistent with accounting guidance, the selling price is based upon vendor specific objective evidence (“VSOE”). If VSOE is not third December 31, 2017 2016, no The Company does not
Customer Advance Payments, Policy [Policy Text Block]	Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products .
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not lly to recognize ( 1 2 3 We utilize a three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2017, no
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company ’s products are generally subject to a one not
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue.
Advertising Costs, Policy [Policy Text Block]	Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2017 2016.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations a s incurred. Research and development costs include, but are not
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company ’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2017 2016. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not cal merits of the position. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not 12
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subje ct to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2017 2016,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company ’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2017 2016 Stock options to purchase common stock 2,694,224 1,909,764 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards 10,000 58,155
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In May 2014, IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014 09, 606 606 606” five not December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 ( 2015 14 2016 08 2016 10 2016 10 May 2016, 2016 12, 606 not May 2014. The Company did not this guidance, and accordingly, will adopt this new standard effective January 1, 2018. 606 605 January 1, 2018, January 1, 2018. As part of its preliminary evaluation, the Company has also considered the impact of the guidance in ASC 340 40, “Other Assets and Deferred Costs; Contracts with Customers”, with respect to capitalization and amortization of incremental costs of obtaining a contract. This guidance, requires the capitalization of all incremental costs that the Company incurs to obtain a contract with a customer that it would not not not not The Company has set up a team for the implementation of the new revenue recognition accou nting standard. Based on preliminary analysis, the Company expects that the new standard will not 606. In July 2015, 2015 11, Simplifying the Measurement of Inventory” (“ASU 2015 11” 2015 11 not first 2015 11 January 1, 2017. not In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, In March 2016, 2016 09, Compensation – Stock Compensation (Topic 718 January 1, 2017 not In August 2016, No. 2016 15, Statement of Cash Flows, Classification of Certain Cash Receipts and Cash Payments (Topic 230 zero December 15, 2017, January 1, 2018 not In August 2016, No. 2016 18, “Statement of Cash Flows, Restricted Cash (Topic 230 December 15, 2017, January 1, 2018 not In May 2017, No. 2017 09, Compensation - Stock Compensation (Topic 718 may 718. December 15, 2017, January 1, 2018 not We have reviewed other recent accounting pronouncements and concluded they are either not no ents as a result of future adoption.

Note 2 - Summary of Significa22

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2017 2016 Stock options to purchase common stock 2,694,224 1,909,764 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards 10,000 58,155

Note 4 - Property and Equipme23

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	Life December 31, (in years) 2017 2016 Medical equipment 5 $ 1,299 $ 657 Computer equipment 3 193 83 Leasehold Improvements 3 200 - Furniture and fixtures 7 340 57 2,032 797 Less: Accumulated depreciation and amortization (729 ) (314 ) Property and equipment, net $ 1,303 $ 483

Note 6 - Accrued Liabilities (T

Note 6 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2017 2016 Accrued bonuses $ 1,597 $ 1,102 Accrued sales commission 1,067 115 Accrued payroll and other related expenses 488 249 Accrued professional fees 562 483 Accrued interest 447 65 Accrued sales & use tax 149 39 Other accruals 295 133 Total accrued liabilities $ 4,605 $ 2,186

Note 7 - Note Payable (Tables)

Note 7 - Note Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2018 $ 2,668 2019 2,778 2020 2,901 2021 16,672 2022 19,306 Thereafter 6,221 Total payments 50,546 Less: Amount representing interest (20,051 ) Present value of obligations 30,495 Less: Unamortized debt discount (1,547 ) Note payable, noncurrent portion $ 28,948

Note 8 - Commitments and Cont26

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2018 $ 338 2019 264 2020 112 Total minimum lease payments $ 714

Note 9 - Common Stock (Tables)

Note 9 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622

Note 10 - Summary of Stock Op28

Note 10 - Summary of Stock Options (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, December 31, 2015 1,022,195 $ 6.47 9.37 $ 1,194,180 Options granted 978,966 $ 6.00 Options exercised (3,020 ) $ 4.80 Options cancelled (88,377 ) $ 7.41 Options outstanding, December 31, 2016 1,909,764 $ 6.19 9.12 $ 211,396 Options granted 1,000,985 $ 5.68 Options exercised (7,730 ) $ 4.02 Options cancelled (208,795 ) $ 8.88 Options outstanding, December 31, 2017 2,694,224 $ 5.80 8.58 $ 249,154 Vested and exercisable and expected to vest, end of period 2,539,133 $ 5.80 8.55 $ 239,624 Vested and exercisable, end of period 843,008 $ 5.86 7.65 $ 116,261
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisabl e Weighte d Numbe r Weighte d Averag e Numbe r Weighte d Outstanding Averag e Remainin g Exercisabl e Averag e Range o f as o f Exercis e Contractua l as o f Exercis e Exercise Price s December 31, 201 7 Pric e Term (Years ) December 31, 201 7 Pric e $2.64 12,500 $ 2.64 7.37 8,334 $ 2.64 $3.68 - $3.76 66,876 $ 3.76 7.10 47,371 $ 3.76 $4.46 - $5.01 542,829 $ 4.72 8.51 183,555 $ 4.75 $5.22 557,358 $ 5.22 8.94 146,696 $ 5.22 $5.46 - $5.67 365,000 $ 5.58 9.72 - $ - $6.00 557,753 $ 6.00 7.96 278,880 $ 6.00 $6.24 - $6.61 122,038 $ 6.44 8.18 36,766 $ 6.32 $7.00 - $7.92 431,492 $ 7.65 8.75 103,028 $ 7.72 $9.92 38,135 $ 9.92 4.89 38,135 $ 9.92 $56.00 - $296.00 243 $ 100.46 2.96 243 $ 100.46 2,694,224 $ 5.80 8.58 843,008 $ 5.86
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2017 2016 Expected term (in years) 5 5 Average volatility 59% 49% Risk-free interest rate 1.89% 1.78% Dividend yield 0% 0% Year Ended December 31, 2017 2016 Expected term (in years) 10 10 Average volatility 72% 51% Risk-free interest rate 2.38% 2.43% Dividend yield 0% 0%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, 2017 2016 Cost of revenue $ 19 $ - Research and development 252 114 Selling, general and administrative 1,601 906 Total $ 1,872 $ 1,020
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2017 Expected term (in years) 0.25 Average volatility 61 % Risk-free interest rate 1.06 % Dividend yield 0 %

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2017 2016 Income tax provision (benefit) at statutory rate (34 )% (34 )% State income taxes, net of federal benefit (4 )% (2 )% Change in valuation allowance 4 % 33 % Effect of tax legislation 33 % 0 % Other 1 % 3 % Effective tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 19,699 $ 16,888 Capitalized start up costs 3,963 5,944 Research and development credits 835 518 Accruals and reserves 1,403 1,095 Fixed assets and depreciation 39 - Total deferred tax assets 25,939 24,445 Deferred tax liabilities: Fixed assets and depreciation - (7 ) Valuation allowance (25,939 ) (24,438 ) Net deferred tax assets $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2017 2016 Balance at the beginning of the year $ 268 $ 128 Additions based upon tax positions related to the current year 129 140 Balance at the end of the year $ 397 $ 268

Note 13 - Segments and Geogra30

Note 13 - Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2017 2016 United States $ 11,004 315 Asia Pacific 3,178 4,946 Europe and Middle East 667 1,489 Latin America 360 382 Canada 79 9 Total $ 15,288 $ 7,141
Long-lived Assets by Geographic Areas [Table Text Block]	Year Ended December 31, 2017 2016 United States $ 1,192 $ 370 Asia Pacific 52 39 Canada 46 2 Latin America 12 - Europe 1 72 Total $ 1,303 $ 483

Note 1 - The Company and Basi31

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Nov. 08, 2017	Mar. 22, 2017	Jun. 17, 2016	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	May 10, 2016
Proceeds from Issuance of Common Stock					$ 31,565,000	$ 13,886,000
Common Stock, Par or Stated Value Per Share				$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
November 2017 ATM Facility [Member]
Aggregate Offering Price	$ 25,000,000
Stock Issued During Period, Shares, New Issues				59,249
Proceeds From Issuance of Common Stock, Net				$ 125,000
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues		8,625,000
Proceeds From Issuance of Common Stock, Net		$ 31,440,000
Share Price		$ 4
Proceeds from Issuance of Common Stock		$ 34,500,000
June 2016 Offering [Member]
Stock Issued During Period, Shares, New Issues			3,105,000
Proceeds From Issuance of Common Stock, Net			$ 13,886,000
Share Price			$ 5
Proceeds from Issuance of Common Stock			$ 15,525,000

Note 2 - Summary of Significa32

Note 2 - Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Number of Financial Institutions	1
Allowance for Doubtful Accounts Receivable	$ 221,000	$ 0
Inventory, Finished Goods, Net of Reserves	1,990,000	2,506,000
Inventory, Raw Materials, Net of Reserves	400,000	$ 181,000
Equity Method Investment, Other than Temporary Impairment	$ 0
Warranty Period	1 year
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years
Medical Equipment, Sales Demos [Member]
Property, Plant and Equipment, Useful Life	5 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Number of Customers	2	3
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Two Customers [Member]
Concentration Risk, Percentage	35.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Three Customers [Member]
Concentration Risk, Percentage		78.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers	2	3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage	57.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage		81.00%

Note 2 - Summary of Significa33

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Stock Option [Member]
Stock options to purchase common stock (in shares)	2,694,224	1,909,764
Common Stock Warrants [Member]
Stock options to purchase common stock (in shares)	642,622	425,274
Restricted Stock [Member]
Stock options to purchase common stock (in shares)	10,000	58,155

Note 4 - Property and Equipme34

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Depreciation	$ 449,000	$ 111,000

Note 4 - Property and Equipme35

Note 4 - Property and Equipment, Net - Equipment, Furniture, and Leasehold Improvements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property and equipment, gross	$ 2,032	$ 797
Less: Accumulated depreciation and amortization	(729)	(314)
Property and equipment, net	$ 1,303	483
Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Property and equipment, gross	$ 1,299	657
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Property and equipment, gross	$ 193	83
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	3 years
Property and equipment, gross	$ 200
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Property and equipment, gross	$ 340	$ 57

Note 5 - Investment in Limite36

Note 5 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Payments to Acquire Equity Method Investments		$ 2,500,000
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		11.00%
InControl Medical [Member] | Distribution Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		1,200
Payments for Purchase of Products		$ 94,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 6 - Accrued Liabilities -

Note 6 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued bonuses	$ 1,597	$ 1,102
Accrued sales commission	1,067	115
Accrued payroll and other related expenses	488	249
Accrued professional fees	562	483
Accrued interest	447	65
Accrued sales & use tax	149	39
Other accruals	295	133
Total accrued liabilities	$ 4,605	$ 2,186

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual) - USD ($)	May 22, 2017	Jun. 20, 2016	May 31, 2017	Dec. 31, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				642,622
Interest Payable				$ 20,051,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Warrant Term		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		100,402		100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.98		$ 4.98
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrant Term	10 years		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049		222,049	222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50		$ 9.50	$ 9.50
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Face Amount		$ 10,000,000
Debt Instrument, Fee, Percentage		4.00%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | First Tranche [Member]
Proceeds from Issuance of Long-term Debt		$ 7,500,000
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Second Tranche [Member]
Proceeds from Issuance of Long-term Debt		$ 2,500,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount	$ 20,000,000
Debt Agreement, Covenant, Additional Funding	10,000,000
Debt Agreement, Maximum Borrowing Capacity	$ 30,000,000
Debt Instrument, Term	6 years
Debt instrument, Interest Only Payment, Period	4 years
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period	4.00%
Paid-in-Kind Interest				$ 495,000
Debt Instrument, Prepayment Fee, Percentage	5.00%
Debt Instrument, Prepayment Fee, Period of Term	5 years
Debt Instrument, Covenant, Cash and Cash Equivalents	$ 2,000,000
The 2017 Loan Agreement [Member] | CRG LP [Member] | Other Noncurrent Liabilities [Member]
Interest Payable				$ 132,000

Note 7 - Note Payable - Summary

Note 7 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
2,018	$ 2,668
2,019	2,778
2,020	2,901
2,021	16,672
2,022	19,306
Thereafter	6,221
Total payments	50,546
Less: Amount representing interest	(20,051)
Present value of obligations	30,495
Less: Unamortized debt discount	(1,547)
Note payable, noncurrent portion	$ 28,948	$ 7,762

Note 8 - Commitments and Cont40

Note 8 - Commitments and Contingencies (Details Textual)	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Feb. 01, 2017USD ($)ft²$ / item
Operating Leases, Rent Expense | $	$ 442,000	$ 236,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²			12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | $ / item			20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | $ / item			21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | $ / item			21.75
Security Deposit | $			$ 22,000
Operating Leases, Allowance for Certain Improvements | $			$ 88,000

Note 8 - Commitments and Cont41

Note 8 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 338
2,019	264
2,020	112
Total minimum lease payments	$ 714

Note 9 - Common Stock (Details

Note 9 - Common Stock (Details Textual) - USD ($)	Nov. 08, 2017	May 31, 2017	May 22, 2017	Mar. 22, 2017	Jun. 20, 2016	Jun. 17, 2016	May 31, 2017	May 19, 2017	Aug. 30, 2016	Jul. 31, 2016	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	May 31, 2015	Sep. 30, 2014
Proceeds from Issuance of Common Stock												$ 31,565,000	$ 13,886,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											642,622	642,622
Debt Instrument, Unamortized Discount											$ 1,547,000	$ 1,547,000
Class of Warrants or Rights, Exercises in Period												4,701	25,268
Allocated Share-based Compensation Expense												$ 1,872,000	$ 1,020,000
The 2016 Loan Agreement [Member]
Amortization of Debt Discount (Premium)												371,000	69,000
Debt Issuance Costs, Net					$ 90,000
The 2017 Loan Agreement [Member]
Amortization of Debt Discount (Premium)												183,000
Debt Issuance Costs, Net		$ 790,000					$ 790,000
Debt Instrument, Unamortized Discount											$ 1,547,000	$ 1,547,000
September 2014 Issuance Related to 2014 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															58,962
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 4.24
Amortization of Debt Discount (Premium)													387,000
Stock Issued During Period, Shares, Exercise of Warrants									17,295
May 2015 Issuance Related to 2014 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														3,125
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 2.96
Stock Issued During Period, Shares, Exercise of Warrants										885
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					100,402						100,402	100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 4.98						$ 4.98	$ 4.98
Warrants and Rights Outstanding					$ 350,000
Warrant Term					10 years
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		222,049	222,049				222,049				222,049	222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 9.50	$ 9.50				$ 9.50				$ 9.50	$ 9.50
Warrants and Rights Outstanding		$ 940,000					$ 940,000
Warrant Term			10 years				10 years
Fair Value Assumptions, Expected Dividend Rate							0.00%
Fair Value Assumptions, Expected Volatility Rate							55.10%
Fair Value Assumptions, Risk Free Interest Rate							2.25%
Fair Value Assumptions, Expected Term		10 years
Allocated Share-based Compensation Expense												$ 0	$ 162,000
Vendors and Contractors Warrants, October and November 2014 Issuance [Member]
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period												0	1,094
Restricted Stock [Member]
Stock Issued During Period, Shares, New Issues								35,000
Shares Issued, Price Per Share								$ 7.42
Stock Issued During Period, Value, New Issues								$ 260,000
November 2017 ATM Facility [Member]
Aggregate Offering Price	$ 25,000,000
Stock Issued During Period, Shares, New Issues											59,249
Proceeds From Issuance of Common Stock, Net											$ 125,000
Stock Issued During Period, Value, New Issues												$ 125,000
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues				8,625,000
Proceeds From Issuance of Common Stock, Net				$ 31,440,000
Stock Issued During Period, Value, New Issues												$ 31,440,000
Share Price				$ 4
Proceeds from Issuance of Common Stock				$ 34,500,000
June 2016 Offering [Member]
Stock Issued During Period, Shares, New Issues						3,105,000
Proceeds From Issuance of Common Stock, Net						$ 13,886,000
Stock Issued During Period, Value, New Issues													$ 13,886,000
Share Price						$ 5
Proceeds from Issuance of Common Stock						$ 15,525,000

Note 9 - Common Stock - Summary

Note 9 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	May 31, 2017	May 22, 2017	Jun. 20, 2016
Shares Outstanding Under Warrants (in shares)	642,622
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	86,831
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4
Shares Outstanding Under Warrants (in shares)	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2.72
Shares Outstanding Under Warrants (in shares)	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5.60
Shares Outstanding Under Warrants (in shares)	26,875
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6.08
Shares Outstanding Under Warrants (in shares)	25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 7.74
Shares Outstanding Under Warrants (in shares)	5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 4.98			$ 4.98
Shares Outstanding Under Warrants (in shares)	100,402			100,402
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 9.50	$ 9.50	$ 9.50
Shares Outstanding Under Warrants (in shares)	222,049	222,049	222,049

Note 10 - Summary of Stock Op44

Note 10 - Summary of Stock Options (Details Textual) - USD ($)	Dec. 29, 2017	Dec. 06, 2017	Dec. 23, 2016	Aug. 22, 2016	Dec. 31, 2017	Oct. 31, 2017	Sep. 30, 2017	Aug. 30, 2017	May 31, 2017	Jan. 31, 2017	Nov. 30, 2016	Sep. 30, 2016	Aug. 31, 2016	Jan. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 05, 2017	Aug. 15, 2017	Aug. 14, 2017	Dec. 22, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					2,694,224										2,694,224	1,909,764	1,022,195
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price					$ 5.80										$ 5.80	$ 6.19	$ 6.47
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term															8 years 211 days	9 years 43 days	9 years 135 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															1,000,985	978,966
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value															$ 31,000	$ 5,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period															7,730	3,020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate															0.00%	0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options					$ 4,547,000										$ 4,547,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition															2 years 292 days
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate															0.00%	0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate															0.00%
Two Thousand Five Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					0										0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					0										0
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					38,378										38,378
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					0										0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price					$ 10.49										$ 10.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term															4 years 321 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					2,655,846										2,655,846
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price					$ 5.73										$ 5.73
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term															8 years 233 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum															10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent															110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock				4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		780,143	523,209
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		4,780,143	2,523,209															4,000,000	4,000,000	2,523,209	2,000,000
Common Stock, Capital Shares Reserved for Future Issuance					1,186,527										1,186,527
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															981,110	919,841
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value															$ 2.88	$ 2.63
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															19,875	59,125
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value															$ 4.09	$ 4.60
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period															0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number					10,000										10,000
The 2013 Plan [Member] | Restricted Stock [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					10,000									39,494
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 4.94									$ 6.24
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period												89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					0					39,405
The 2013 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period						7,884	6,947		4,797		6,544		5,998
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value						$ 5.55	$ 5.58		$ 7.07		$ 5.91		$ 7.89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period						7,884	6,947		4,797		6,544		5,998
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period												1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period												25,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value												$ 7.58
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															5 years
The 2013 Plan [Member] | Quarterly [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period															25,000
2017 Employee Stock Purchase Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance								400,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee								2,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date								85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Offering Period								90 days
Stock Issued During Period, Shares, Employee Stock Purchase Plans	17,894
Employee Stock Purchase Plan, Purchase Price	$ 4.2245
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares					382,106										382,106
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate															0.00%
2017 Employee Stock Purchase Plan [Member] | Weighted Average [Member]
Share Price					$ 1.51										$ 1.51

Note 10 - Summary of Stock Op45

Note 10 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Options outstanding, Shares (in shares)	1,909,764	1,022,195
Options outstanding, Weighted average exercise price (in dollars per share)	$ 6.19	$ 6.47
Options outstanding, Weighted Average Remaining Contractual Term (Year)	8 years 211 days	9 years 43 days	9 years 135 days
Options outstanding, Aggregate Intrinsic Value	$ 249,154	$ 211,396	$ 1,194,180
Options granted, Shares (in shares)	1,000,985	978,966
Options granted, Weighted average exercise price (in dollars per share)	$ 5.68	$ 6
Options exercised, Shares (in shares)	(7,730)	(3,020)
Options exercised, Weighted average exercise price (in dollars per share)	$ 4.02	$ 4.80
Options canceled, Shares (in shares)	(208,795)	(88,377)
Options canceled, Weighted average exercise price (in dollars per share)	$ 8.88	$ 7.41
Options outstanding, Shares (in shares)	2,694,224	1,909,764	1,022,195
Options outstanding, Weighted average exercise price (in dollars per share)	$ 5.80	$ 6.19	$ 6.47
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares)	2,539,133
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share)	$ 5.80
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term (Year)	8 years 200 days
Vested and exercisable and expected to vest, end of period, Aggregate Intrinsic Value	$ 239,624
Vested and exercisable, end of period, Number Of Shares (in shares)	843,008
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share)	$ 5.86
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term (Year)	7 years 237 days
Vested and exercisable, end of period, Aggregate Intrinsic Value	$ 116,261

Note 10 - Summary of Stock Op46

Note 10 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Options outstanding, number (in shares) | shares	2,694,224
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.80
Options outstanding, weighted average remaining contractual term (Year)	8 years 211 days
Options exercisable, number exercisable (in shares) | shares	843,008
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.86
Range One [Member]
Exercise price range, lower limit (in dollars per share)	2.64
Exercise price range, upper limit (in dollars per share)	$ 2.64
Options outstanding, number (in shares) | shares	12,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.64
Options outstanding, weighted average remaining contractual term (Year)	7 years 135 days
Options exercisable, number exercisable (in shares) | shares	8,334
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.64
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	3.68
Exercise price range, upper limit (in dollars per share)	$ 3.76
Options outstanding, number (in shares) | shares	66,876
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.76
Options outstanding, weighted average remaining contractual term (Year)	7 years 36 days
Options exercisable, number exercisable (in shares) | shares	47,371
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.76
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	4.46
Exercise price range, upper limit (in dollars per share)	$ 5.01
Options outstanding, number (in shares) | shares	542,829
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.72
Options outstanding, weighted average remaining contractual term (Year)	8 years 186 days
Options exercisable, number exercisable (in shares) | shares	183,555
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.75
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	5.22
Exercise price range, upper limit (in dollars per share)	$ 5.22
Options outstanding, number (in shares) | shares	557,358
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.22
Options outstanding, weighted average remaining contractual term (Year)	8 years 343 days
Options exercisable, number exercisable (in shares) | shares	146,696
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.22
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	5.46
Exercise price range, upper limit (in dollars per share)	$ 5.67
Options outstanding, number (in shares) | shares	365,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.58
Options outstanding, weighted average remaining contractual term (Year)	9 years 262 days
Options exercisable, number exercisable (in shares) | shares
Options exercisable, weighted average exercise price (in dollars per share)
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	6
Exercise price range, upper limit (in dollars per share)	$ 6
Options outstanding, number (in shares) | shares	557,753
Options outstanding, weighted average exercise price (in dollars per share)	$ 6
Options outstanding, weighted average remaining contractual term (Year)	7 years 350 days
Options exercisable, number exercisable (in shares) | shares	278,880
Options exercisable, weighted average exercise price (in dollars per share)	$ 6
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	6.24
Exercise price range, upper limit (in dollars per share)	$ 6.61
Options outstanding, number (in shares) | shares	122,038
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.44
Options outstanding, weighted average remaining contractual term (Year)	8 years 65 days
Options exercisable, number exercisable (in shares) | shares	36,766
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.32
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	7
Exercise price range, upper limit (in dollars per share)	$ 7.92
Options outstanding, number (in shares) | shares	431,492
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.65
Options outstanding, weighted average remaining contractual term (Year)	8 years 273 days
Options exercisable, number exercisable (in shares) | shares	103,028
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.72
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	9.92
Exercise price range, upper limit (in dollars per share)	$ 9.92
Options outstanding, number (in shares) | shares	38,135
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, weighted average remaining contractual term (Year)	4 years 324 days
Options exercisable, number exercisable (in shares) | shares	38,135
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.92
Range Ten [Member]
Exercise price range, lower limit (in dollars per share)	56
Exercise price range, upper limit (in dollars per share)	$ 296
Options outstanding, number (in shares) | shares	243
Options outstanding, weighted average exercise price (in dollars per share)	$ 100.46
Options outstanding, weighted average remaining contractual term (Year)	2 years 350 days
Options exercisable, number exercisable (in shares) | shares	243
Options exercisable, weighted average exercise price (in dollars per share)	$ 100.46

Note 10 - Summary of Stock Op47

Note 10 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Expected term (in years) (Year)	5 years	5 years
Average volatility	59.00%	49.00%
Risk-free interest rate	1.89%	1.78%
Dividend yield	0.00%	0.00%
2017 Employee Stock Purchase Plan [Member]
Expected term (in years) (Year)	91 days
Average volatility	61.00%
Risk-free interest rate	1.06%
Dividend yield	0.00%

Note 10 - Summary of Stock Op48

Note 10 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Expected term (in years) (Year)	5 years	5 years
Average volatility	59.00%	49.00%
Risk-free interest rate	1.89%	1.78%
Dividend yield	0.00%	0.00%
Nonemployees [Member]
Expected term (in years) (Year)	10 years	10 years
Average volatility	72.00%	51.00%
Risk-free interest rate	2.38%	2.43%
Dividend yield	0.00%	0.00%

Note 10 - Summary of Stock Op49

Note 10 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Allocated share-based compensation expense	$ 1,872	$ 1,020
Cost of Sales [Member]
Allocated share-based compensation expense	19
Research and Development Expense [Member]
Allocated share-based compensation expense	252	114
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 1,601	$ 906

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ 1,501,000	$ 5,750,000
Deferred Tax Assets, Tax Credit Carryforwards, Research		835,000	518,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued		0
Unrecognized Tax Benefits		$ 397,000	$ 268,000	$ 128,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		34.00%	34.00%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards		$ 78,858,000
Deferred Tax Assets, Tax Credit Carryforwards, Research		701,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards		50,517,000
Deferred Tax Assets, Tax Credit Carryforwards, Research		$ 623,000

Note 11 - Income Taxes - Provis

Note 11 - Income Taxes - Provision for Income Taxes Computed at Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income tax provision (benefit) at statutory rate	(34.00%)	(34.00%)
State income taxes, net of federal benefit	(4.00%)	(2.00%)
Change in valuation allowance	4.00%	33.00%
Effect of tax legislation	33.00%	0.00%
Other	1.00%	3.00%
Effective tax rate	0.00%	0.00%

Note 11 - Income Taxes - Signif

Note 11 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 19,699	$ 16,888
Capitalized start up costs	3,963	5,944
Research and development credits	835	518
Accruals and reserves	1,403	1,095
Fixed assets and depreciation	(39)
Total deferred tax assets	25,939	24,445
Deferred tax liabilities:
Fixed assets and depreciation		(7)
Valuation allowance	(25,939)	(24,438)
Net deferred tax assets

Note 11 - Income Taxes - Unreco

Note 11 - Income Taxes - Unrecognized Tax Benefit Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Balance	$ 268,000	$ 128,000
Additions based upon tax positions related to the current year	129,000	140,000
Balance	$ 397,000	$ 268,000

Note 12 - Related Party Trans54

Note 12 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	12 Months Ended		123 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017
Stock Issued During Period, Shares, New Issues			37,500
Related Party Transaction, Amounts of Transaction	$ 7,912,000	$ 6,485,000

Note 13 - Segments and Geogra55

Note 13 - Segments and Geographic Information - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 15,288	$ 7,141
UNITED STATES
Revenue	11,004	315
Asia Pacific [Member]
Revenue	3,178	4,946
Europe And Middle East [Member]
Revenue	667	1,489
Latin America [Member]
Revenue	360	382
CANADA
Revenue	$ 79	$ 9

Note 13 - Long-lived Assets by

Note 13 - Long-lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Long-lived assets	$ 1,303	$ 483
UNITED STATES
Long-lived assets	1,192	370
Asia Pacific [Member]
Long-lived assets	52	39
CANADA
Long-lived assets	46	2
Latin America [Member]
Long-lived assets	12
Europe [Member]
Long-lived assets	$ 1	$ 72

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($)	Feb. 12, 2018	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Proceeds from Issuance of Common Stock				$ 31,565,000	$ 13,886,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues			59,249
Proceeds From Issuance of Common Stock, Net			$ 125,000
Subsequent Event [Member] | February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	11,500,000
Share Price	$ 3
Proceeds from Issuance of Common Stock	$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 32,380,000
Subsequent Event [Member] | November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues		208,277
Proceeds From Issuance of Common Stock, Net		$ 1,025,000